Will Berinert's US OK for self-administration put Shire's Firazyr on the run?
This article was originally published in Scrip
With the US FDA granting CSL Behring permission to market its hereditary angioedema (HAE) drug Berinert, a plasma-derived C1 inhibitor replacement product, as a self-administered medicine for acute abdominal, facial or laryngeal swelling attacks, the company may have Shire's Firazyr (icatibant) on the run, although as a subcutaneously administered treatment, the latter may still win out.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.